The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer

2 型糖尿病、胰腺炎和癌症中的外分泌和内分泌胰腺

• 批准号: 10254446
• 负责人: GLORIA M. PETERSEN
• 金额: $ 47.7万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-28 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10254446
• 关键词: Abdominal Pain; Admission activity; Ancillary Study; Awareness; Biological; Biological Markers; Biometry; Clinic; Clinic Activity; Clinical; Clinical Research; Communities; Consult; Diabetes Mellitus; Diagnosis; Diagnostic; Discipline; Disease; Early Diagnosis; Enrollment; Ensure; Environment; Epidemiology; Evaluation; Exocrine pancreas; Goals; Heterogeneity; Incidence; Infrastructure; Institution; Internet; Islets of Langerhans; Knowledge; Laboratories; Lead; Leadership; Life Expectancy; Link; Longitudinal cohort; Longitudinal cohort study; Malignant Neoplasms; Malignant neoplasm of pancreas; Measures; Medical; Modification; Morbidity - disease rate; Newly Diagnosed; Non-Insulin-Dependent Diabetes Mellitus; Outpatients; Pain; Pain management; Pancreas; Pancreatic Diseases; Pancreatitis; Participant; Patients; Protocols documentation; Research; Research Infrastructure; Research Personnel; Research Support; Role; Salivary; Sample Size; Solid; Techniques; Training; Validation; acute pancreatitis; base; chronic pancreatitis; clinical phenotype; clinical practice; cohort; design; epidemiology study; experience; improved; mortality; prospective; recruit; stem; tool; working group

PROJECT SUMMARY / ABSTRACT Since the inception of the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) Consortium, the Mayo Clinic team has been an active participant, including leadership roles, in multiple initiatives. A key priority of the Consortium is the facilitation of mechanism-based research of chronic pancreatitis, pancreatogenic diabetes mellitus, and pancreatic cancer through systematically collected clinical measures in longitudinal cohort studies linked with biospecimens. The goal of the Mayo Clinic team is to contribute meaningfully to the most useful longitudinal cohorts that will increase our understanding of clinical, epidemiological, and biological characterization of patients with these conditions. The primary longitudinal cohort initiatives (outlined in the PAR) to which Mayo Clinic will continue to contribute are PROCEED and NOD. Mayo Clinic investigators will also extend ancillary studies in PROCEED (salivary biomarkers and internet based pain management techniques for pain in chronic pancreatitis (IMPACT)) that leverage the extensive infrastructure in place. The Consortium has defined three Working Groups (WG) in which Mayo Clinic investigators contribute and provide leadership (chronic pancreatitis (CP), Type 3c diabetes mellitus (T3cDM); pancreatic cancer-DM WG. Our contribution includes solid accrual rates for these studies to date, and successful completion of one ancillary study by the PI, active participation in the design of the NOD cohort and subsequent modifications, and extending accrual for DETECT. Using the existing, highly productive infrastructure we have established, our Specific Aims are to: 1) Continue to prospectively enroll and expand accrual of 100 Mayo patients into the PROCEED cohort. Using the clinical research infrastructure in place, we will also enroll chronic pancreatitis patients and subjects into ancillary studies within the CPDPC that include, among others: salivary biomarkers, MINIMAP, and PAIR. 2) Continue to prospectively enroll and expand accrual of 1,322 newly diagnosed diabetes patients into the NOD study. 3) Continue to lead and extend prospective accrual of 60 Mayo participants into the DETECT study. To accomplish these aims, we will implement and identify new strategies to improve recruitment into the main studies as well as ancillary studies at Mayo Clinic while providing to the CPDPC the scientific, clinical and recruitment experience of our investigators.

项目摘要 /摘要 自慢性胰腺炎，糖尿病和胰腺癌（CPDPC）的研究开始以来 财团，梅奥诊所团队一直是一个积极的参与者，包括领导角色， 倡议。财团的关键优先事项是促进基于机制的慢性研究 通过系统收集的临床，胰腺炎，胰腺糖尿病和胰腺癌 纵向队列研究与生物测量有关的措施。梅奥诊所团队的目标是 有意义地为最有用的纵向人群做出贡献，这将增加我们对临床的理解， 具有这些条件的患者的流行病学和生物学表征。主要纵向 Mayo诊所将继续贡献到的同类倡议（在标准杆中概述）是继续进行的 点头。梅奥诊所研究人员还将扩展辅助研究（唾液生物标志物和 基于互联网的疼痛管理技术用于慢性胰腺炎（影响）） 广泛的基础设施。该财团定义了三个工作组（WG），其中蛋黄酱 诊所研究人员贡献并提供领导力（慢性胰腺炎（CP），3C糖尿病类型 （T3CDM）;胰腺癌-DM WG。我们的贡献包括迄今为止这些研究的稳定应计率， 并成功完成了PI的一项辅助研究，积极参与点头队列的设计 和随后的修改，并扩展应计检测。使用现有的高生产力 我们已经建立的基础设施，我们的具体目的是： 1）继续前瞻性地招募和扩大100名蛋黄酱患者的应计纳入继续队列。 使用临床研究基础设施，我们还将注册慢性胰腺炎患者和 在CPDPC内进行辅助研究的受试者包括：唾液生物标志物， 最小值，配对。 2）继续前瞻性地招募和扩大1,322名新诊断的糖尿病患者的应计入 点头研究。 3）继续领导和扩展60位Mayo参与者的预期应计入检测研究。 为了实现这些目标，我们将实施并确定新的策略，以将招聘改善为主要 在Mayo诊所进行的研究以及辅助研究，同时为CPDPC提供了科学，临床和 我们调查人员的招聘经验。